Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Bitcoin ETF (BITO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

ProShares Bitcoin ETFTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

ProShares Bitcoin ETF vs Charles River Laboratories Intl. Inc — how do they compare? ProShares Bitcoin ETF trades at $8.77, while Charles River Laboratories Intl. Inc trades at $231.21 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITOCRL
Sector
Crypto-linkedHealth
52-Week High
$22.93$233.60
52-Week Low
$7.98$145.57
Market Cap
$11.14B
Enterprise Value
$14.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Bitcoin ETF

BITO trades at $8.44, down 2.65% today amid bearish technical signals with 12 sell indicators versus 4 buy signals. The ETF faces challenges with declining distributions and negative sentiment as crypto markets struggle. Recent dividend payments of $0.01-$0.02 per share provide limited offset to the fund's 24.26% five-year decline.

The outlook remains cautious with structural costs and Bitcoin correlation concerns weighing on performance. Key risks include management fee drag, distribution volatility, and crypto market exposure. Investors should monitor fee structure efficiency and Bitcoin market stability for potential recovery catalysts.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

About ProShares Bitcoin ETF

BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.

Read more on BITO

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL